Emergence of the concept of platelet reactivity monitoring of response to thienopyridines

被引：18

作者：

Bonello, L. ^{[1
,2
,3
]}

De Labriolle, A. ^{[1
]}

Scheinowitz, M. ^{[1
]}

Lemesle, G. ^{[4
,5
]}

Roy, P. ^{[1
]}

Steinberg, D. H. ^{[1
]}

Slottow, T. L. Pinto ^{[1
]}

Pakala, R. ^{[1
]}

Pichard, A. D. ^{[1
]}

Barragan, P. ^{[6
]}

Camoin-Jau, L. ^{[3
]}

Dignat-George, F. ^{[3
]}

Paganelli, F. ^{[2
]}

Waksman, R. ^{[1
]}

机构：

[1] Washington Hosp Ctr, Dept Internal Med, Div Cardiol, Washington, DC 20010 USA

[2] Hop Univ Nord Marseille, Dept Cardiol, Marseille, France

[3] Hop Conception, INSERM, UMRS 608, UFR Pharm,Lab Hematol, Marseille, France

[4] Ctr Hosp Reg & Univ Lille, Hop Cardiol, Serv Cardiol B, F-59037 Lille, France

[5] Ctr Hosp Reg & Univ Lille, Hop Cardiol, Ctr Hemodynam, F-59037 Lille, France

[6] Clin Fleurs, Dept Cardiol, Ollioules, France

来源：

HEART | 2009年 / 95卷 / 15期

关键词：

VASODILATOR-STIMULATED PHOSPHOPROTEIN; PERCUTANEOUS CORONARY INTERVENTION; INTRAPLATELET VASP PHOSPHORYLATION; ADVERSE CARDIOVASCULAR EVENTS; FLOW-CYTOMETRIC ANALYSIS; STENT THROMBOSIS; CLOPIDOGREL RESISTANCE; ANTIPLATELET THERAPY; CLINICAL-OUTCOMES; ARTERY-DISEASE;

D O I：

10.1136/hrt.2008.152660

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Clinical trials have demonstrated the beneficial impact of clopidogrel in preventing major adverse cardiovascular events (MACE), particularly in patients undergoing percutaneous coronary intervention (PCI). The concept of biological clopidogrel resistance emerged with the finding of persistent platelet activation despite clopidogrel therapy in some patients. Further, a link between biological clopidogrel resistance and thrombotic recurrence after PCI was observed and a threshold of platelet reactivity (PR) for thrombotic events was suggested. Consistently, in recent trials, enhanced PR inhibition translated into a reduction in the rate of MACE after PCI. This review aims to present the emergence of the concept of PR monitoring in patients undergoing PCI following recent advances in this field.

引用

页码：1214 / 1219

页数：6

共 33 条

[1] Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases [J].

Aleil, B ;

Ravanat, C ;

Cazenave, JP ;

Rochoux, G ;

Heitz, A ;

Gachet, C .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (01) :85-92

[2] Resistance to thienopyridines: Clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation [J].

Barragan, P ;

Bouvier, JL ;

Roquebert, PO ;

Macaluso, G ;

Commeau, P ;

Comet, B ;

Lafont, A ;

Camoin, L ;

Walter, U ;

Eigenthaler, M .

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2003, 59 (03) :295-302

[3] Increased risk in patients with high platelet amregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention - Is the current antiplatelet therapy adequate? [J].

Bliden, Kevin P. ;

DiChiara, Joseph ;

Tantry, Udaya S. ;

Bassi, Ashwani K. ;

Chaganti, Srivasavi K. ;

Gurbel, Paul A. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (06) :657-666

[4] The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis [J].

Blindt, Ruediger ;

Stellbrink, Katja ;

de Taeye, Anita ;

Mueller, Robert ;

Kiefer, Paul ;

Yagmur, Eray ;

Weber, Christian ;

Kelm, Malte ;

Hoffmann, Rainer .

THROMBOSIS AND HAEMOSTASIS, 2007, 98 (06) :1329-1334

[5] Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events [J].

Bonello, L. ;

Paganelli, F. ;

Arpin-Bornet, M. ;

Auquier, P. ;

Sampol, J. ;

Dignat-George, F. ;

Barragan, P. ;

Camoin-Jau, L. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (08) :1630-1636

[6] Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: A multicenter randomized prospective study [J].

Bonello, Laurent ;

Camoin-Jau, Laurence ;

Arques, Stephane ;

Boyer, Christian ;

Panagides, Dimitri ;

Wittenberg, Olivier ;

Simeoni, Marie-Claude ;

Barragan, Paul ;

Dignat-George, Francoise ;

Paganelli, Franck .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (14) :1404-1411

[7] Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis [J].

Buonamici, Piergiovanni ;

Marcucci, Rossella ;

Migliorini, Angela ;

Gensini, Gian Franco ;

Santini, Alberto ;

Paruccia, Rita ;

Moschi, Guia ;

Gori, Anna Maria ;

Abbate, Rosanna ;

Antoniucci, David .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (24) :2312-2317

[8] Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting [J].

Cuisset, Thomas ;

Frere, Corinne ;

Quilici, Jacques ;

Morange, Pierre-Emmanuel ;

Nait-Saidi, Lyassine ;

Carvajal, Joseph ;

Lehmann, Agnes ;

Lambert, Marc ;

Bonnet, Jean-Louis ;

Alessi, Marie-Christine .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 48 (07) :1339-1345

[9] ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome [J].

Frere, Corinne ;

Cuisset, Thomas ;

Quilici, Jacques ;

Camoin, Laurence ;

Carvajal, Joseph ;

Morange, Pierre Emmanuel ;

Lambert, Marc ;

Juhan-Vague, Irene ;

Bonnet, Jean-Louis ;

Alessi, Marie-Christine .

THROMBOSIS AND HAEMOSTASIS, 2007, 98 (04) :838-843

[10] Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease [J].

Geisler, T. ;

Kapp, M. ;

Goehring-Frischholz, K. ;

Daub, K. ;

Doesch, C. ;

Bigalke, B. ;

Langer, H. ;

Herdeg, C. ;

Gawaz, M. .

HEART, 2008, 94 (06) :743-747

← 1 2 3 4 →